ClinicalTrials.gg
RecruitingNCT07121894Updated Aug 17, 2026

Ketogenic Intervention for Bipolar Depression

An interventional study of Ketogenic Diet in Bipolar Depression, sponsored by Mayo Clinic. Recruiting at 1 site in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2025; still recruiting 1 year 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.

Planned enrollment
7th of 12
30 · median 35
Started
2025
with 1 other
No phase
3 of 13
2 open now
Registered
10th of 13
by date

Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 7th largest by planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is one of 3 with no phase, and was the 10th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bipolar Disorder by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to assess the clinical correlates of therapeutic precision ketosis in bipolar depression and to evaluate the cardiometabolic correlates associated with therapeutic precision ketosis in bipolar depression.

03

Conditions studied

  • Bipolar Depression

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-50 years
  • Willingness to change the current diet to a high fat, low carbohydrate diet
  • Diagnosis of bipolar I or II disorder, or BP schizoaffective Disorder by (SCID- confirmed). If a participant has already completed a structured diagnostic interview within the last 2 years or in any of the Department of Psychiatry and Psychology Mood Unit studies, existing SCID results can be used for this study; thus, they will not be required to repeat the SCID assessment. If a structured diagnostic interview was completed more than 2 years ago, the current mood state sections of the SCID must be repeated to ensure accuracy of current mood state assessment.
  • Depressive symptom severity of at least mild (MADRS > 6) with steady and stable (ie, at least 2 weeks) mood stabilization (eg, lithium, valproate, lamotrigine, carbamazepine/oxcarbamazepine, and/or atypical antipsychotic therapy) and non-psychotropic medication.
  • Urine drug screen is negative except for allowable drugs that they have been prescribed, such as benzodiazepines.
  • Pregnancy test is negative.
  • Established practice for sexually active individuals.
  • Medical comorbidity is stable (hypertension, T2D, gout - uric acid in normal limits).

Exclusion criteria

Exclusion Criteria:

  • No access to smartphone or internet (unless provided by sponsor)
  • Inability to provide written, voluntary, and pass (80%) comprehension assessment related to study goals, risks, and benefits.
  • Structured clinical interview confirmation of schizophrenia or presence of psychotic symptoms (both SCID and YMRS question 8>5).
  • Clinical diagnosis of personality disorder that, upon review by the study psychiatrist, of all available information (SCID, electronic health record), is the primary psychiatric diagnosis.
  • Mixed symptoms of depression defined as a YMRS ≥12 (i.e., hypomania).
  • Active suicidal ideation as defined by MADRS score >4 on question #10 or Columbia Suicide Severity Scale (C-SSRS), yes response to Question #4 (ideation, intent, but no plan) or Question #5 (ideation, intent, and plan).
  • Any current drug and alcohol use disorder (excluding nicotine); complete (not partial) remission ≥3 months.
  • Positive toxicology screen for cannabis and cannabis use disorder by structured clinical interview. Participants who use cannabis for recreational or medicinal purposes and fail the toxicology screen can potentially be included if the Cannabis Use Disorder Identification Test (CUDIT-R) score is \< 12.
  • Currently undergoing ECT, transcranial magnetic stimulation, or deep brain stimulation as an acute or maintenance treatment. Maintenance vagal nerve stimulation is allowed if the placement of device is > 1 year.
  • Current involuntary psychiatric hospitalization.
  • Already in ketosis or on a medication that causes acidosis, such as carbonic anhydrase inhibitors (e.g., acetazolamide "Diamox" and topiramate).
  • \< 18.5; (m) baseline LDL-c > 190.
  • Any active or unstable medical condition judged by the principal investigator as conferring significant medical risk to allow inclusion in the study, such as active severe infection.
  • Acute pancreatitis or history of lipid-associated pancreatitis.
  • Type I diabetes.
  • SGLT2 inhibitor use
  • Rare inborn errors of metabolism affecting fatty acid processing (typically diagnosed in infancy or, rarely, adolescence), such as Pyruvate carboxylase deficiency and Porphyria
  • Primary carnitine deficiency
  • Chronic renal failure, significant renal disease defined as \<30 or in dialysis.
  • Severe vitamin D deficiency (serum levels of 25-hydroxyvitamin D [25(OH)D] \< 12 ng/mL or 30 nMol/L). Participants with abnormal vitamin D levels would be eligible if they begin supplementation and vitamin D levels are normalized before Baseline.
  • A diagnosis of osteopenia, defined as a bone mineral density (BMD) T-score between -1.0 and -2.5 on a dual-energy X-ray absorptiometry (DEXA) scan or with a history of fragility fractures
  • laboratory test abnormality
  • Anticipated elective surgical procedure within the next 18 weeks
  • Family history of premature coronary artery disease defined as atherosclerotic cardiovascular events (e.g., heart attack, stroke) before 55 and 65 years of age in male and female first-degree relatives, respectively.
  • History of familial hypercholesterolemia (note -current or start of statin or lipid-lowering drug as part of clinical care is not an exclusion provided managed by a primary care provider) or LDL-C>190 mg/dl (or LDL>160 mg/dl if on lipid lowering therapy) or triglycerides>500 mg/dl.
  • History of coronary disease or coronary calcifications or coronary stenosis found in invasive cardiac catheterization or imaging.
  • History of ischemic stroke or carotid plaque found on baseline common carotid intima-media thickness (IMT) ultrasound.
  • History of peripheral atherosclerotic arterial disease or any other form of clinical atherosclerosis.
  • History or current diagnosis of respiratory failure defined as a PaO₂ \< 60 mmHg or SpO₂ \< 90% on room air or any condition leading to clinically significant respiratory impairment
  • History or current diagnosis of liver failure or chronic liver disease with significant impairment, defined as or AST > 5 times the , or total > 3 mg/dL.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ketogenic Diet

    Patients diagnosed with bipolar disorder and experiencing depression or depressive symptoms.

    Behavioral: Ketogenic Diet

Interventions

  • BehavioralKetogenic Diet

    Participants will initiate a modified ketogenic diet under structured, intensive guidance. Simultaneously, participants will attend weekly behavioral support interviews with a psychiatrist to monitor mental health and mood stability.

06

What researchers measure

Primary outcomes

  1. Change in depressive symptoms

    Measured using the Quick Inventory for Depressive Symptomatology Clinician Rated (QIDS-C), a 16-item clinician rating, each rated on a four-point Likert scale (0-3). The total score ranges from 0 to 27. The QIDS-C is scored by summing the responses to the 16 items, with higher scores indicating more severe symptoms.

    Time frame: Baseline, 6 months

Secondary outcomes

  1. Response and Remission Rates

    Measured using the Montgomery-Asberg Depression Rating Scale (MADRS), with response defined as a ≥50% reduction from baseline symptoms and remission as a score \<10, providing complementary measures of symptom improvement. MADRS is a 10-item observer rating scale assessing symptoms of depression. The MADRS will be used to assess depression severity, exclude patients with suicidal ideation scoring \> 4 on question #10 and measure % of patients achieving remission defined as a MADRS \< 10.

    Time frame: Baseline, 6 months

  2. Percentage of clinically significant improvement

    The proportion of participants rated as "much improved" or "very much improved" on the Clinical Global Impression for Bipolar Disorder (CGI-BP) scale. CGI-BP is a specialized tool for assessing the severity, treatment response, and efficacy of interventions in bipolar disorder. It addresses the unique features of the disorder by evaluating manic and depressive episodes separately. It consists of three components: Severity of Illness (CGI-BP-S), Global Improvement (CGI-BP-I), which tracks changes from baseline; and Efficacy Index (CGI-BP-E), which assesses treatment benefits relative to side effects.

    Time frame: Baseline, 6 months

  3. Change in anxiety symptoms

    Measured using the General Anxiety Disorder 7 (GAD-7), a 7-item self-report questionnaire used to measure the severity of generalized anxiety symptoms over the past two weeks. Each item is scored on a 4-point Likert scale (0 = "Not at all" to 3 = "Nearly every day"), with a total score ranging from 0 to 21. Higher scores indicate greater anxiety severity

    Time frame: Baseline, 6 months

  4. Prevalence rate of disordered eating

    Measured using the Eating Disorder Diagnostic Scale (EDDS), a standardized measure designed to assess symptoms of eating disorders. It quantifies symptom severity and provides a diagnostic algorithm based on threshold scores that indicate probable diagnoses and subthreshold levels of disordered eating. The EDDS includes 22 items that evaluate key behaviors and cognitive symptoms associated with eating disorders.

    Time frame: 6 months

  5. Change in psychosocial functioning

    Measured using the Functioning Assessment Short Test (FAST),a short, simple interview-administered instrument for patients with psychiatric disorders to assess functional recovery. The psychometric properties of this test enable it to detect differences between euthymic and acute patients with bipolar disorder. The total FAST score is the sum of each item. Lower scores indicate good functioning, while higher scores indicate increased impairment.

    Time frame: Baseline, 6 months

  6. Change in well-being

    Measured using the Well-Being Index (WHO-5), a self-report instrument measuring mental well-being. It consists of five statements relating to the past two weeks. Each statement is rated on a 6-point scale, with higher scores indicating better mental well-being.

    Time frame: Baseline, 6 months

  7. Change in insulin resistance

    Insulin resistance will be assessed using calculated Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) from fasting glucose and insulin levels.

    Time frame: Baseline, 6 months

  8. Change in mitochondrial function

    Assessed by evaluating baseline-to-endpoint changes in mitochondrial metabolites, measured using the MMPP test developed at Mayo Clinic.

    Time frame: Baseline, 6 months

  9. Change in serum levels of high sensitivity C-reactive protein (CRP)

    High sensitivity C-reactive protein (CRP) is an acute-phase protein produced by the liver in response to systemic inflammation and is widely used as a biomarker of inflammation. These changes will be analyzed in conjunction with daily ketone body measurements, providing an index of ketosis.

    Time frame: Baseline, 6 months

  10. Change in subclinical vascular health

    Assessed by changes in key vascular function and structure indicators. This includes detailed assessments of lipid profiles, focusing on biomarkers such as apolipoprotein B and advanced high-resolution lipoprotein subfraction profiling.

    Time frame: Baseline, 6 months

  11. Change in interleukin-6 IL-6

    Interleukin-6 (IL-6) is a cytokine involved in immune response and inflammation. These changes will be analyzed in conjunction with daily ketone body measurements, providing an index of ketosis, and mood state assessments to explore potential correlations.

    Time frame: Baseline, 6 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Dec 2028, 40 months after the start.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 40 months is close to that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 14, 2025
StartActual
Aug 12, 2025
Primary completionEst.
Dec 31, 2028
CompletionEst.
May 1, 2029
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07121894
Lead sponsor
Mayo Clinic
Responsible party
Kyla M. Lara-Breitinger (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Aug 14, 2025
Start date
Aug 12, 2025
Primary completion
Dec 31, 2028 (estimated)
Completion
May 1, 2029 (estimated)
Last update
Aug 17, 2026

Study contacts

Karin Lindstrom, PhD
Contact
Lindstrom.Karin@mayo.edu
507-293-3876
Kyla M. Lara-Breitinger, MD
principal investigator · Mayo Clinic
Mark Frye, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion